Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 5,967 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the sale, the chief executive officer owned 613,029 shares of the company’s stock, valued at $3,009,972.39. This represents a 0.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, April 6th, Kevin Lee sold 1,716 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $5.05, for a total value of $8,665.80.

Bicycle Therapeutics Trading Down 3.2%

NASDAQ BCYC opened at $4.89 on Tuesday. The stock has a 50-day simple moving average of $5.33 and a 200 day simple moving average of $6.57. The company has a market capitalization of $340.88 million, a PE ratio of -1.55 and a beta of 1.65. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $4.24 and a 12 month high of $9.55.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.71. The business had revenue of $47.96 million during the quarter, compared to the consensus estimate of $7.08 million. Bicycle Therapeutics had a negative return on equity of 33.21% and a negative net margin of 301.66%. As a group, sell-side analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.

Bicycle Therapeutics News Summary

Here are the key news stories impacting Bicycle Therapeutics this week:

• Neutral Sentiment: Multiple executives sold stock to cover tax withholding on vested awards — CEO Kevin Lee sold a total of 7,683 shares across April 2 and April 6 (average prices ~$4.91–$5.05), COO Jennifer Scott Perry sold 1,408 shares under a pre‑arranged 10b5‑1 plan, and CFO Travis Thompson sold 901 shares. Sales were disclosed on SEC Form 4s and described as tax‑related rather than opportunistic cash‑outs, which mutes but does not eliminate negative investor reaction to visible insider selling. CEO Form 4 COO Form 4 CFO Form 4
• Neutral Sentiment: Analyst coverage remains mixed and the consensus is a “Hold” from the group of brokers covering BCYC (MarketBeat notes the consensus). A hold consensus provides limited near‑term buying pressure and can reinforce cautious sentiment following insider sales. Analyst Consensus Article

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Royal Bank Of Canada dropped their price objective on Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating for the company in a report on Wednesday, March 18th. Truist Financial set a $8.00 price objective on Bicycle Therapeutics in a report on Tuesday, March 17th. Citizens Jmp lowered their price target on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a report on Wednesday, March 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Finally, Oppenheimer lowered their price target on Bicycle Therapeutics from $44.00 to $36.00 and set an “outperform” rating for the company in a report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Institutional Investors Weigh In On Bicycle Therapeutics

Several large investors have recently modified their holdings of the business. Fcpm Iii Services B.V. increased its holdings in shares of Bicycle Therapeutics by 0.5% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company’s stock worth $24,556,000 after acquiring an additional 16,100 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock worth $22,911,000 after acquiring an additional 258,000 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Bicycle Therapeutics by 2.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company’s stock worth $21,353,000 after buying an additional 63,483 shares during the period. GSK plc acquired a new position in shares of Bicycle Therapeutics during the fourth quarter worth about $10,829,000. Finally, Long Focus Capital Management LLC boosted its position in shares of Bicycle Therapeutics by 7.7% during the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after buying an additional 101,402 shares during the period. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.